Malignant melanoma is one of the most aggressive neoplasms in skin and eye and is associated with a high incidence of metastasis. The survival of patients with malignant melanoma has improved during the past several decades, due to earlier diagnosis and surgical excision of primary malignant melanoma. Despite these advances, approximately 15% of patients with malignant melanoma die of this disease.
Malignant melanoma is one of the most aggressive neoplasms in skin and eye and is associated with a high incidence of metastasis. The survival of patients with malignant melanoma has improved during the past several decades, due to earlier diagnosis and surgical excision of primary malignant melanoma. Despite these advances, approximately 15% of patients with malignant melanoma die of this disease. 1) There is no effective therapy for metastatic melanoma. Many attempts have been made to evoke or amplify an immune response against melanoma, since it is one of the most immunogenic tumors.
2) Cytokine therapy and tumor-infiltrating lymphocyte immunotherapy were partially effective in inducing melanoma regression, but caused auto-immune problems such as vitiligo, poliosis, uveitis and meningitis as a result of melanocyte destruction.
2) Thus, a new therapeutic method such as gene therapy is needed, and attempts have been made to introduce genes encoding cytokines and a costimulatory factor into tumor cells by the use of viral and nonviral vectors. 3) Previously, we reported experimental therapy of squamous cell carcinomas in vivo using an immunotoxin, and showed that a monoclonal anti-human epidermal growth factor (EGF) receptor antibody B4G7 4) exhibited excellent targeting ability. 5, 6) With this same antibody, we developed a novel gene delivery system, in which the Fab fragment of B4G7 antibody is conjugated to poly-L-lysine (pLys) to form an affinity complex with DNA. 7) This Fab fragment/DNA complex was designated as "Fab immunogene," 8, 9) by analogy with immunotoxin. To date, we have demonstrated that the immunogene can deliver various reporter genes and therapeutic genes in vitro into EGF receptor-overproducing A431 tumor cells of squamous carcinoma origin. 7) Melanoma cell lines often produce a large amount of transforming growth factor (TGF)-α [10] [11] [12] and EGF receptor, [13] [14] [15] [16] which together stimulate the growth of cells through an EGF receptor-mediated autocrine mechanism. 17, 18) Thus, the targeted delivery of therapeutic genes into melanoma cells might also be accomplished by the Fab immunogene system. In this article, we present evidence that the Fab immunogene delivers the β-galactosidase (β-Gal) reporter gene into melanoma cells through EGF receptors. Moreover, the delivery of suicide genes by the Fab immunogene followed by treatment with prodrugs is effective in suppressing the growth of melanoma cells both in vitro and ex vivo.
MATERIALS AND METHODS
Cells and cell culture HMV-I and G361 are derived from human vaginal and cutaneous melanomas. 19, 20) Y79 is derived from a retinoblastoma. 21) HMV-I and Y79 were obtained from the RIKEN Cell Bank (Tsukuba). G361 was obtained from the Health Science Research Resources Bank (Osaka). HMV-I was maintained in Ham F-12 medium plus 10% fetal calf serum. G361 and a cervical carcinoma cell line HeLa were maintained in Dulbecco's modified Eagle's medium plus 10% fetal calf serum. Y79 was maintained in RPMI1640 medium plus 10% fetal calf serum. Cell cultures were incubated at 37°C in a humidified atmosphere of 5% CO 2 in air. EGF receptor on melanoma cells EGF receptor on the melanoma cell surface was analyzed by immunofluorescent staining, immunoblotting and 125 I-EGF binding. For immunofluorescent staining, cells were grown on a cover glass, fixed with acetone, treated with monoclonal anti-human EGF receptor antibody B4G7 at 4°C, and then treated with FITC-labeled goat anti-mouse IgG antibody. 22) For immunoblot analysis of the EGF receptor, 23) cells were lysed with Tris-buffered saline (0.15 M NaCl, 50 mM Tris-HCl pH 7.4, 0.1 mM phenylmethylsulfonyl fluoride) containing 1% Triton X-100. Cell lysates were clarified by centrifugation and incubated with B4G7 antibody bound to protein A Sepharose (Pharmacia Biotech, Uppsala, Sweden). Immunoprecipitates were electrophoresed on sodium dodecyl sulfate (SDS)-polyacrylamide gel and transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA). The EGF receptors on a blot were visualized by incubation with sheep anti-human EGF receptor antibody (Upstate Biotech. Inc., Lake Placid, NY), with biotinylated anti-sheep IgG antibody and avidin-biotin-alkaline-phosphatase complex (Vector Lab., Burlington, CA).
EGF binding assay was carried out using 125 I-EGF. 23) Cells in 24-well culture plates were placed on ice and incubated with 125 I-EGF in phosphate-buffered saline (PBS) for 1 h. The cell-bound EGF was solubilized with 0.5 N NaOH and the radioactivity was determined in Beckman 5500 gamma counter. Plasmid preparation pCMV is an expression vector with the cytomegalovirus promoter, the NheI-SpeI-deleted plasmid of pBK-CMV (Stratagene, La Jolla, CA). Escherichia coli cytosine deaminase (CD) gene 24) was amplified from E. coli DNA by polymerase chain reaction (PCR) using a pair of primers (5′-GGAATTCGCCACCATGGTGTC-GAATAACGCTTTAC-3′ and 5′-GGAATTCAGTCGT-TCAACGTTTGTAAT-3′). The amplified CD gene was inserted into the EcoRI site of the plasmid pSRD, 25) affording the mammalian expression vector pSRD-CD driven by SRα promoter, 8) and the EcoRI site of pCMV. E. coli β-Gal expression vectors, pSRD-β-Gal and pCMV-β-Gal, were constructed as follows: a β-Gal gene fragment, HindIII-DraI fragment of pSV-β-Gal (Promega, Madison, WI), was inserted into the EcoRI site of pSRD and the HindIII-ScaI site of pCMV. Herpes simplex virus thymidine kinase (TK) expression vector pSRD-TK was described previously.
8)
Preparation of Fab immunogene (Fab/pLys/DNA complex) Fab immunogene was prepared as described previously. 7, 8) B4G7 antibody was digested to produce Fab fragments. The Fab fragment was modified with sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (Pierce, Rockford, IL). pLys (average molecular mass 44 kDa, Sigma, St. Louis, MO) was modified with 2-iminothiolane (Sigma). The modified Fab fragment was mixed with an equal weight of modified pLys to form a conjugate via a thio-ether bond. The resulting conjugate (designated Fab immunoporter) was separated from nonconjugated Fab fragment by cation-exchange chromatography on a Mono S HR 5/5 column (Pharmacia Biotech.) using an NaCl gradient. The conjugate fractions were filtered through a 0.22 µm MILLEX-GV filter (Millipore) to ensure sterility. The Fab immunoporter was then mixed with various amounts of DNA and incubated for 30 min at room temperature. The resulting Fab immunoporter/ DNA complex (designated, for example, β-Gal/Fab immunogene) was applied to cells for measurement of reporter gene expression. β β β β-Gal gene expression in melanoma cells Cells were treated with the β-Gal/Fab immunogene (2 µg of pSRD-β-Gal DNA/2 µg of Fab immunoporter in 50 µl of 0.1 M HEPES pH 7.3, 150 mM NaCl) for 72 h in culture medium (37°C, 5% CO 2 ). β-Gal gene expression was detected as described. , 1×10 7 cells in 100 µl of PBS with 10 µg pSRD-TK or pSRD-CD DNA/10 µg Fab immunoporter) and injected subcutaneously into the back of Balb/ c nu/nu mice (4-to 6-week-old females, Sankyo Laboservice Co., Tokyo). Then, GCV (100 µg/mouse) or 5-FC (5 mg/mouse) was injected intraperitoneally 6 h after the cell injection and again every other day. The tumor weight was determined by measuring the major (L) and minor (S) axes of the tumor and calculated by using the formula W (mg)=0.5×L(mm)×S(mm) 2 .
6)

RESULTS
EGF receptors on melanoma cells
We first examined how many EGF receptors are present in melanoma cells by three different methods. Immunofluorescent staining using anti-human EGF receptor antibody B4G7 revealed significant levels of EGF receptor in two melanoma cell lines (HMV-I and G361) and HeLa cells (Fig. 1A) . Immunoblot analysis showed the mature EGF receptor of 170 kDa in both melanoma cell lines, as seen in HeLa cells, but not in the retinoblastoma cell line Y79 (Fig.  1B) . (Fig. 2A) . On the other hand, the β-Gal expressing cells in the immunogene-treated G361 melanoma cell population amounted to approximately 0.5% regardless of promoter type (Fig. 2A) . No β-Gal-expressing cells were found among the receptor-negative Y79 cells ( Fig. 2A) . In melanoma cells, the β-Gal-expressing cells appeared within a day and increased for 4 days (Fig. 2B) . A nonspecific immunoporter consisting of mouse non-specific IgG and pLys did not deliver the β-Gal gene into melanoma cells (data not shown). Interestingly, the liposomemediated β-Gal gene transfer was equally effective (approximately 1%) in these three cell lines regardless of the numbers of EGF receptors (data not shown). These results are consistent with our previous observation using squamous carcinoma cell lines that the Fab immunogene transfer of β-Gal gene is processed through the EGF receptors.
7)
Suicide gene transfer to melanoma cells Melanoma cells were treated with the Fab immunogene carrying TK gene for 6 h and then with GCV for 4 days. GCV itself was not cytotoxic to melanoma cells even at the high concentration of 100 µM (Fig. 3A) . However, those melanoma cells became extremely sensitive to GCV after TK/ Fab immunogene transfer: the 50% lethal dose (LD 50 ) was 5 µM for HMV-I and 40 µM for G361 cells, an 8-fold difference (Fig. 3A) .
Similar experiments were carried out using the Fab immunogene carrying CD gene and 5-FC (Fig. 3B) . 5-FC itself was not cytotoxic to melanoma cells up to 10 mM. However, the CD/Fab immunogene transfer made those cells very sensitive to 5-FC: LD 50 was 30 µM for HMV-I and 4 mM for G361 cells (Fig. 3B) . It is noteworthy that HMV-I melanoma cells are more sensitive than the other cell line G361 and that the CD/Fab immunogene system is apparently more effective than the TK/Fab immunogene system.
The cell suicide effects induced by the TK/Fab immunogene and CD/Fab immunogene were significantly reduced when HMV-I cells were pretreated with excess amounts of Fab fragments (P<0.01, by Mann-Whitney's U test) (Fig. 4) , again indicating the receptor specificity of gene transfer. As expected, pretreatment with non-specific IgG did not reduce the suicide effects (data not shown).
The suppression of melanoma cell growth by the CD/ Fab immunogene transfer followed by 5-FC treatment presence of GCV or 5-FC. We examined if it is equally effective in vivo by performing an ex vivo study. HMV-I melanoma cells were mixed with TK/Fab immunogene or CD/Fab immunogene in vitro and injected subcutaneously into the back of nude mice. The effective dose and interval of injection were determined in preliminary experiments to be 3-8 mg of 5-FC (i.e., 300-800 mg of 5-FC/ kg of body weight) and every day or every other day, respectively (data not shown). Under this ex vivo condition, the immunogene-bearing melanoma cells grew and developed tumors, whereas tumor growth was significantly suppressed if GCV or 5-FC was administered intraperitoneally (Fig. 6, A, B and C) . Thus, transfer of the TK gene or CD gene as a form of Fab immunogene and subsequent systemic administration of GCV or 5-FC induced substantial suicide of HMV-I melanoma cells in nude mice. 
DISCUSSION
Previously, we developed a targeted gene delivery system using the Fab fragment of monoclonal antibody cross-linked with a cationic polymer (pLys) to which DNA binds. We designated this complex "Fab immunogene" by analogy with "immunotoxin." 8) We have documented the unique features of immunogene in terms of its receptor-specific binding and internalization, intracellular endocytic processing, and gene expression in the nucleus, using squamous carcinoma cells which overproduce EGF receptors. 7) In this study, we applied the Fab immunogene transfer system to human melanoma cells, which also produce a large number of EGF receptors.
The frequency of β-Gal-expressing cells was approximately 1%, which is as high as the lipofection method can achieve in those melanoma cells. The Fab immunogene transfer was dependent on the presence of EGF receptor. Interestingly, the Fab immunogene transfer was equally effective in two melanoma cell lines regardless of the number of EGF receptors (0.3-3×10 5 ). This is consistent with our previous finding that the transfer efficiency of β-Gal/Fab immunogene is not directly related to the receptor number and the post-receptor processes are rate-limiting. 7) In this study, despite the relatively low transfer efficiency, we were able to induce substantial growth inhibition of melanoma cells by suicide gene and prodrug treatment under in vitro and ex vivo conditions. These observations justify further refinement of the Fab immunogene system, aiming at gene therapy for melanoma.
Melanoma is one of the most immunogenic tumors and therefore gene therapy studies so far have attempted to evoke anti-tumor immunity to the melanoma itself in the patient. 3, 26) One approach utilized melanoma cells transfected with cytokine genes. 27) Another approach utilized melanoma cells transfected with co-stimulatory molecules such as B7 to prime naive T cells or to restimulate resting T cells. 28) In these cases, therapeutic genes are introduced into melanoma cells ex vivo or by intratumoral injection using viral vectors or liposome/DNA complex. More recent approaches utilized dendritic cells or muscle transfected with DNA encoding melanoma-specific antigen to induce a systemic T-and B-cell activation. 3, 29) Another important approach is a targeted delivery of therapeutic genes to melanoma cells to induce cell suicide effects. 30, 31) In the present study, we employed two cell suicide systems, TK/GCV and CD/5-FC, both of which effectively inhibited the growth of melanoma cells in vitro and ex vivo. In these suicide systems, the transferred suicide genes produce enzymes which can convert a nontoxic compound (prodrug) to a toxic metabolite, and hence the toxic metabolite is selectively produced in transfected tumor cells. The enzyme TK converts a relatively nontoxic prodrug GCV to the highly toxic nucleotide analog, which is transported into neighboring cells through cell-cell gap junctions and eventually inhibits DNA replication.
31) The other enzyme, CD, catalyzes conversion of the nontoxic prodrug 5-FC to highly toxic 5-FU, which can freely diffuse across the plasma membrane into neighboring cells independently of cell-cell gap junctions and eventually inhibits their growth. 24) Thus, the antitumor effect of the metabolite takes place even in the neighboring tumor cells (so-called bystander effect). 24, 30, 31) Melanoma cells build only loose cell-cell junctions, and therefore the CD/5-FC system was expected to be more effective than TK/GCV, and in fact this was the case. The remarkable growth suppression in vivo despite the relatively low transfection efficiency of the Fab immunogene could be accounted for by the bystander effect. 7, 32) Our immunogene approach toward melanoma gene therapy has several advantages as compared to virus vector systems.
9) The Fab immunogene can form affinity complexes with any genes under any control elements and thus it is easy to adapt for the delivery of cytokine and co-stimulatory factor genes. Fab immunogene is specific to EGF receptor-producing tumor cells but additional security might be provided with the use of a transcriptional control element such as the tyrosinase promoter, which is specific to melanocytes and melanoma. 29) Besides the EGF receptor, melanoma cells can be targeted by antibodies against melanoma-specific membrane antigens such as MART-1 and gp100. 33) We are now pursuing in vivo immunogene studies using melanoma-bearing nude mice and immuno-suppressed rabbits. It is our hope that the Fab immunogene system may eventually allow systemic treatment of inoperable metastatic melanomas.
